Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in treatment-resistant sarcoidosis
2016-003360-39Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Apr 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in sarcoidosis and pulmonary sarcoidosis, sponsored by Universitätsklinikum Freiburg. Primary endpoint: Severe infectious complications during Abatacept treatment. Started Apr 2017; status: completed.
02
Drugs
abatacept
03
Conditions
sarcoidosispulmonary sarcoidosis
Beyond the preview
Go deeper on 2016-003360-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003360-39.